宫颈癌与人乳头状瘤病毒相关研究进展_West China Medical Journal

Authors：

巴彩霞 , 张丹彤 , 杨艳红 , 赵紫罡

Corresponding author：

Keywords：

宫颈癌; 人乳头状瘤病毒; 疫苗

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

【摘要】　宫颈癌严重威胁女性健康，已成为发展中国家的第二位最常见的肿瘤死亡原因。宫颈癌的发生、发展与人乳头状瘤病毒感染密切相关，进一步明确人乳头状瘤病毒感染在宫颈癌发病机制中所起的作用，具有重大的研究价值。寻找宫颈癌早期的最佳筛查方案，研制有效的预防人乳头状瘤病毒感染疫苗将为人类攻克宫颈癌带来新的希望。

Citation： 巴彩霞,张丹彤,杨艳红,赵紫罡. 宫颈癌与人乳头状瘤病毒相关研究进展. West China Medical Journal, 2011, 26(4): 632-635. doi: Copy

1.	Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide[J]. J Pathol, 1999, 189(1): 12-19.
2.	Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical cancer (IBSCC) Study Group[J]. J Natl Cancer Inst, 1995, 87(11): 796-802.
3.	Ault KA. Epidemiology and natural history of human papillomavirus infections in the female genital tract[J]. Infect Dis Obstet Gynecol, 2006, 194(Suppl): 40470.
4.	Scheurer ME, Tortolero-Luna G, Adler-Storthz K. Human papillomavirus infection: biology, epidemiology, and prevention[J]. Int J Gynecol Cancer, 2005, 15(5): 727-746.
5.	Munoz N, Castellsague X, de Gonzalez AB, et al. Chapter 1: HPV in the etiology of human cancer[J]. Vaccine, 2006, 24 (Suppl 3):1-3.
6.	Schiller JT, Davies P. Delivering on the promise: HPV vaccines and cervical cancer[J]. Nat Rev Microbiol, 2004, 2(4): 343-347.
7.	Kim CJ, Jeong JK, Park M, et al. HPV oligonucleotide microarray-based detection of HPV genotypes in cervical neoplastic lesions.[J]. Gynecol Oncol, 2003, 89(2): 210-217.
8.	Motoyama S, Ladines-Llave CA, Luis VS, et al. The role of human papilloma virus in the molecular biology of cervical carcinogenesis[J]. Kobe J Med Sci, 2004, 50(1): 9-19.
9.	Peralta-Zaragoza O, Bermudez-Morales VH, Madrid-Marina V. RNA interference: biogenesis molecular mechanisms and its applications in cervical cancer[J]. Rev Invest Clin, 2010, 62(1): 63-80.
10.	Beaudenon S, Huibregtse JM. HPV E6, E6AP and cervical cancer[J]. BMC Biochem, 2008, 9(Suppl 1): 4.
11.	Tomaic V, Pim D, Banks L. The stability of the human papillomavirus E6 oncoprotein is E6AP dependent[J]. Virology, 2009, 393(1): 7-10.
12.	Wang X, Wang HK, Mccoy JP, et al. Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6[J]. RNA, 2009, 15(4): 637-647.
13.	Martin CM, Astbury K, Mcevoy L, et al. Gene expression profiling in cervical cancer: identification of novel markers for disease diagnosis and therapy[J]. Methods Mol Biol, 2009, 511(2): 333-359.
14.	Watson R. European women’s group calls for human papillomavirus testing[J]. BMJ, 2001, 323(7316): 772.
15.	Castle PE, Solomon D, Wheeler CM, et al. Human papillomavirus genotype specificity of hybrid capture 2[J]. J Clin Microbiol, 2008, 46(8): 2595-2604.
16.	Kimball KJ, Huh WK. Cytology versus high-risk HPV testing for follow-up of HPV-positive women without CIN[J]. J Natl Compr Canc Netw, 2008, 6(1): 96-100.
17.	Castle PE. The potential utility of HPV genotyping in screening and clinical management[J]. J Natl Compr Canc Netw, 2008, 6(1): 83-95.
18.	Growdon WB, Del CM. Human papillomavirus-related gynecologic neoplasms: screening and prevention[J]. Rev Obstet Gynecol, 2008, 1(4): 154-161.
19.	Gravitt PE, Paul P, Katki HA, et al. Effectiveness of VIA, Pap, and HPV DNA testing in a cervical cancer screening program in a peri-urban community in Andhra Pradesh, India[J]. PLoS One, 2010, 5(10): 13711.
20.	Castle PE, Sideri M, Jeronimo J, et al. Risk assessment to guide the prevention of cervical cancer[J]. Am J Obstet Gynecol, 2007, 197(4): 351-356.
21.	Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial[J]. Lancet, 2004, 364(9447): 1757-1765.
22.	FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)[J]. Morb Mortal Wkly Rep, 2010, 59(20): 626-629.
23.	Rambout L, Hopkins L, Hutton B, et al. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials[J]. CMAJ, 2007, 177(5): 469-479.
24.	Stanley M, Lowy DR, Frazer I. Prophylactic HPV vaccines: underlying mechanisms[J]. Vaccine, 2006, 24(Suppl 3): 3-106.
25.	Bolhassani A, Mohit E, Rafati S. Different spectra of therapeutic vaccine development against HPV infections[J]. Hum Vaccin, 2009, 5(10): 671-689.
26.	Brandsma JL, Shlyankevich M, Zelterman D, et al. Therapeutic vaccination of rabbits with a ubiquitin-fused papillomavirus E1, E2, E6 and E7 DNA vaccine[J]. Vaccine, 2007, 25(33): 6158-6163.

1. 　Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide[J]. J Pathol, 1999, 189(1): 12-19.
2. 　Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical cancer (IBSCC) Study Group[J]. J Natl Cancer Inst, 1995, 87(11): 796-802.
3. 　Ault KA. Epidemiology and natural history of human papillomavirus infections in the female genital tract[J]. Infect Dis Obstet Gynecol, 2006, 194(Suppl): 40470.
4. 　Scheurer ME, Tortolero-Luna G, Adler-Storthz K. Human papillomavirus infection: biology, epidemiology, and prevention[J]. Int J Gynecol Cancer, 2005, 15(5): 727-746.
5. 　Munoz N, Castellsague X, de Gonzalez AB, et al. Chapter 1: HPV in the etiology of human cancer[J]. Vaccine, 2006, 24 (Suppl 3):1-3.
6. 　Schiller JT, Davies P. Delivering on the promise: HPV vaccines and cervical cancer[J]. Nat Rev Microbiol, 2004, 2(4): 343-347.
7. 　Kim CJ, Jeong JK, Park M, et al. HPV oligonucleotide microarray-based detection of HPV genotypes in cervical neoplastic lesions.[J]. Gynecol Oncol, 2003, 89(2): 210-217.
8. 　Motoyama S, Ladines-Llave CA, Luis VS, et al. The role of human papilloma virus in the molecular biology of cervical carcinogenesis[J]. Kobe J Med Sci, 2004, 50(1): 9-19.
9. 　Peralta-Zaragoza O, Bermudez-Morales VH, Madrid-Marina V. RNA interference: biogenesis molecular mechanisms and its applications in cervical cancer[J]. Rev Invest Clin, 2010, 62(1): 63-80.
10. 　Beaudenon S, Huibregtse JM. HPV E6, E6AP and cervical cancer[J]. BMC Biochem, 2008, 9(Suppl 1): 4.
11. 　Tomaic V, Pim D, Banks L. The stability of the human papillomavirus E6 oncoprotein is E6AP dependent[J]. Virology, 2009, 393(1): 7-10.
12. 　Wang X, Wang HK, Mccoy JP, et al. Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6[J]. RNA, 2009, 15(4): 637-647.
13. 　Martin CM, Astbury K, Mcevoy L, et al. Gene expression profiling in cervical cancer: identification of novel markers for disease diagnosis and therapy[J]. Methods Mol Biol, 2009, 511(2): 333-359.
14. 　Watson R. European women’s group calls for human papillomavirus testing[J]. BMJ, 2001, 323(7316): 772.
15. 　Castle PE, Solomon D, Wheeler CM, et al. Human papillomavirus genotype specificity of hybrid capture 2[J]. J Clin Microbiol, 2008, 46(8): 2595-2604.
16. 　Kimball KJ, Huh WK. Cytology versus high-risk HPV testing for follow-up of HPV-positive women without CIN[J]. J Natl Compr Canc Netw, 2008, 6(1): 96-100.
17. 　Castle PE. The potential utility of HPV genotyping in screening and clinical management[J]. J Natl Compr Canc Netw, 2008, 6(1): 83-95.
18. 　Growdon WB, Del CM. Human papillomavirus-related gynecologic neoplasms: screening and prevention[J]. Rev Obstet Gynecol, 2008, 1(4): 154-161.
19. 　Gravitt PE, Paul P, Katki HA, et al. Effectiveness of VIA, Pap, and HPV DNA testing in a cervical cancer screening program in a peri-urban community in Andhra Pradesh, India[J]. PLoS One, 2010, 5(10): 13711.
20. 　Castle PE, Sideri M, Jeronimo J, et al. Risk assessment to guide the prevention of cervical cancer[J]. Am J Obstet Gynecol, 2007, 197(4): 351-356.
21. 　Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial[J]. Lancet, 2004, 364(9447): 1757-1765.
22. 　FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)[J]. Morb Mortal Wkly Rep, 2010, 59(20): 626-629.
23. 　Rambout L, Hopkins L, Hutton B, et al. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials[J]. CMAJ, 2007, 177(5): 469-479.
24. 　Stanley M, Lowy DR, Frazer I. Prophylactic HPV vaccines: underlying mechanisms[J]. Vaccine, 2006, 24(Suppl 3): 3-106.
25. 　Bolhassani A, Mohit E, Rafati S. Different spectra of therapeutic vaccine development against HPV infections[J]. Hum Vaccin, 2009, 5(10): 671-689.
26. 　Brandsma JL, Shlyankevich M, Zelterman D, et al. Therapeutic vaccination of rabbits with a ubiquitin-fused papillomavirus E1, E2, E6 and E7 DNA vaccine[J]. Vaccine, 2007, 25(33): 6158-6163.

West China Medical Journal

宫颈癌与人乳头状瘤病毒相关研究进展

Abstract Full text Figures/Tables Video References Cited by

Format

Content